4 FDA PDUFA Dates — Week of June 29–30, 2026

The Drug and the Label Expansion

ZORYVE cream 0.3% is a topical phosphodiesterase-4 inhibitor. The pending supplemental NDA seeks to extend the plaque psoriasis indication to children ages 2 to 5. Arcutis has already established ZORYVE as a commercial dermatology franchise, and ZORYVE cream 0.3% is already indicated for plaque psoriasis in adults and pediatric patients aged 6 years and older. The current review is therefore not a first-in-class unknown molecule trying to obtain its first approval; it is a pediatric label expansion for an established topical product.

The FDA accepted the sNDA in November 2025 and set the target action date for June 29, 2026. Arcutis said the application is supported by a 4-week Maximal Usage Systemic Exposure study in children ages 2 to 5 with plaque psoriasis, as well as data from a long-term open-label study including children in that age range. That matters because pediatric topical labels often depend heavily on systemic exposure, tolerability and safety under conditions that approximate real-world overuse or high-exposure scenarios.

Why the Risk Is Structurally Lower Than a Primary NDA

The risk is not zero — FDA decisions are never zero-risk — but the structure is favorable. The active ingredient, formulation logic and mechanism are already familiar to regulators. The incremental question is whether younger children can be added safely to the plaque psoriasis label. The review is centered on exposure, safety and label language rather than a de novo efficacy debate. That is a very different setup from an unapproved systemic drug with a single pivotal dataset.

Commercial and Financial Context

Arcutis is no longer a pre-commercial biotech. Q1 2026 net product revenue for ZORYVE was $105.4 million, up 65% year over year, according to the company’s May 2026 update. That revenue scale changes the interpretation of the catalyst. A favorable decision would be useful and strategically clean, but the stock’s fundamental story is increasingly tied to execution, prescription growth, gross-to-net dynamics, operating leverage and the company’s ability to expand ZORYVE across inflammatory skin diseases.

For traders, this means ARQT may not behave like a classic all-or-nothing PDUFA. The likely market focus after the decision would be label wording, the speed of pediatric commercial messaging, payer response, physician adoption and management commentary around 2026 sales guidance. A delay or unexpected CRL would be negative, but it would not erase the existing ZORYVE commercial base.

The Diagnostic Asset

LNTH-2501 is a kit for the preparation of Gallium-68 edotreotide injection, a PET diagnostic imaging agent intended for localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. In practical terms, it sits inside a well-established medical workflow: somatostatin receptor imaging helps physicians stage NETs, assess disease burden and select appropriate candidates for therapy, including peptide receptor radionuclide therapy.

The product is not designed to become a blockbuster therapeutic drug. Its strategic value is different. For Lantheus, the asset expands an already strong radiopharmaceutical diagnostics platform and deepens the company’s position in oncology imaging. That is important because Lantheus has built its public-market identity around nuclear medicine, most visibly through PYLARIFY in prostate cancer.

The Three-Month Extension

The original target action date was pushed out by three months to June 29, 2026. Lantheus said the extension allows the FDA additional time to review further manufacturing-related information and is not related to LNTH-2501 efficacy or safety data. This is the central point in the setup. A CMC extension does not guarantee approval, but it is materially different from a negative clinical signal.

Radiopharmaceutical products are technically demanding. The FDA must be comfortable with manufacturing controls, radionuclide purity, sterility, kit preparation, labeling, quality systems and distribution processes. Even when efficacy is not the problem, manufacturing questions can produce approval delays. That is why the LNTH setup should not be dismissed as risk-free simply because the company says efficacy and safety are not at issue.

Business Context

Lantheus reported Q1 2026 worldwide revenue of $377.3 million. PYLARIFY generated $240.9 million, DEFINITY generated $84.6 million, and Neuraceq contributed $35.4 million. The company also reported GAAP diluted EPS of $1.80 and adjusted diluted EPS of $1.46 for the quarter. This is a profitable diagnostics company, not a small-cap development-stage biotech.

That commercial maturity lowers existential risk but also changes upside expectations. A favorable LNTH-2501 decision would add portfolio depth and potentially strengthen the company’s radiopharmaceutical ecosystem, but it is unlikely to be the only determinant of valuation. The market will still care about PYLARIFY trajectory, competition, margins, capital allocation and the broader pipeline.

The Drug and the Market

Oxylanthanum Carbonate is an investigational oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease on dialysis. Hyperphosphatemia is a common and clinically serious issue in dialysis because the kidneys can no longer clear phosphate efficiently. Poor phosphate control is linked to vascular calcification, bone disease and cardiovascular risk. The commercial opportunity exists because many existing phosphate binders are limited by pill burden, tolerability, adherence and meal-by-meal dosing complexity.

Unicycive’s pitch is that OLC could improve adherence and phosphorus control with a reduced pill burden versus currently available phosphate binders. The regulatory pathway is supported by clinical, preclinical and CMC data, and the company has emphasized that the original FDA review did not identify deficiencies in clinical, preclinical or safety data.

Why This Is the Highest-Risk Catalyst in the Group

UNCY’s setup is binary because the company has already received one CRL and because the current decision is tied to whether the FDA is satisfied with the manufacturing resolution. The prior CRL was linked to the compliance status of a third-party manufacturing vendor. A Class II resubmission means the FDA is taking a full six-month review window, not a short two-month administrative review.

This does not mean the outcome is likely negative. It means the event is consequential. If the FDA accepts the manufacturing fix and approves OLC, Unicycive can advance toward commercial readiness, reimbursement work, launch planning and possible partnering. If the FDA issues another CRL, the market will immediately question the company’s balance-sheet runway, negotiating leverage and ability to fund another regulatory cycle.

Financial Position

Unicycive reported $57.1 million in unaudited cash, cash equivalents and marketable securities as of May 11, 2026, and said it believes those resources are sufficient to fund planned operations into 2027. Q1 2026 R&D expense was $1.6 million, G&A expense was $6.8 million, and net comprehensive loss attributable to common stockholders was $12.8 million, or $0.54 per share. The low R&D spend reflects that OLC is past the major clinical-development phase, but a launch or a new regulatory cycle can still require meaningful capital.

The Asset and the Disease

Veligrotug is an intravenous anti-IGF-1R monoclonal antibody for thyroid eye disease, an autoimmune condition that affects orbital tissues and can cause proptosis, diplopia, pain, inflammation and vision-threatening complications. The target is clinically validated by TEPEZZA, the first approved therapy for TED. Viridian’s goal is not to invent a completely new market from scratch, but to enter a market with established medical need and compete on clinical profile, dosing, convenience, tolerability and label breadth.

The FDA accepted the veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date. Veligrotug also received Breakthrough Therapy Designation. Viridian’s Q1 2026 update stated that field teams have been hired and deployed, commercial supply and distribution infrastructure are ready, and the company is preparing for a potential first commercial launch.

Phase 3 and Competitive Context

Viridian’s TED package includes pivotal data in active and chronic TED. Across pivotal trials, the company says veligrotug demonstrated rapid onset, clinically meaningful improvements in proptosis and diplopia, durable responses and general tolerability after five infusions. This matters because TEPEZZA established the category, but a second approved anti-IGF-1R agent could create meaningful commercial competition if the label and launch execution are clean.

Viridian has also reported positive topline data from both pivotal Phase 3 trials of elegrobart, its subcutaneous anti-IGF-1R program. REVEAL-1 in active TED and REVEAL-2 in chronic TED both met their primary endpoints, according to the company. Viridian plans to submit a BLA for elegrobart in Q1 2027. This gives VRDN a two-layer TED story: near-term veligrotug launch potential and a follow-on subcutaneous program that could become more convenient for patients over time.

Financial Position

Viridian reported $762.2 million in cash, cash equivalents and marketable securities as of March 31, 2026, compared with $874.7 million at year-end 2025. That is a large cash position relative to most small/mid-cap biotech launch stories, but launch execution can still consume capital quickly. The stronger balance sheet reduces near-term financing risk, especially compared with smaller binary names, but it does not remove commercial execution risk.